Grant: Discovery Grants Program - Individual
University of Windsor
$34,000.00
Metal-organic Frameworks as Controlled Release Materials
EF 2024-25
Résumé
Billions of dollars each year are spent on the discovery of new pharmaceuticals that offer safer, more effective treatments for diseases and ailments. Drug release materials offer a way to drastically improve medications we already have available by controlling when, where, and how rapidly pharmaceuticals are released. However, current drug release materials, largely based on organic polymers, lipids, and metallic nanoparticles, suffer from low drug loadings, poor control over drug release kinetics, stability problems, and a variety of reproducibility issues. In this research program, we will take advantage of a new class of materials known as Metal-organic Frameworks (MOFs), which offers several potential advantages over currently used materials due to their higher drug loading capabilities and their high degree of modularity/reproducibility. In particular, we will target a new subclass of materials in which the Active Pharmaceutical Ingredient or API is directly encapsulated/incorporated in the MOF material during synthesis, thus avoiding the ineffective post-synthetic loading methods used to incorporate drugs into current release materials. Over the course of this research, we will work towards developing a universal protocol for the direct incorporation of any small molecule pharmaceutical into a controllable MOF drug release matrix. We will target the development of nano-crystalline materials with favorable drug release rates which can also be activated to release their drug payload when exposed to an appropriate stimulus such as light or a high acidity environment. This multi-disciplinary research program offers a unique training environment for the next generation of innovative Canadian scientists and involves aspects of inorganic chemistry, organic chemistry, and materials science. The advancement of nanotechnologies for drug release is a rapidly growing area, and this research program offers the possibility to develop better medications and new technologies within Canada, leading to an economic benefit and increased quality of life for all Canadians.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2020-04570
Name nom
Vukotic, Vedran
Department département
Chemistry and Biochemistry
Organization id
37
Institution établissement
University of Windsor
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2020
Award amount
34000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1208
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Materials sciences
Area of application fr
Sciences des matériaux
Research subject code
3604
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Solid state inorganic chemistry
Research subject fr
Chimie inorganique -- état solide
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Metal-organic Frameworks as Controlled Release Materials
Keywords
metal-organic frameworks; crystal engineering; drug release materials; stimuli-responsive materials; inorganic chemistry; materials chemistry; supramolecular chemistry; functional materials; nano-crystals; inorganic coordination polymers
Application summary
Billions of dollars each year are spent on the discovery of new pharmaceuticals that offer safer, more effective treatments for diseases and ailments. Drug release materials offer a way to drastically improve medications we already have available by controlling when, where, and how rapidly pharmaceuticals are released. However, current drug release materials, largely based on organic polymers, lipids, and metallic nanoparticles, suffer from low drug loadings, poor control over drug release kinetics, stability problems, and a variety of reproducibility issues. In this research program, we will take advantage of a new class of materials known as Metal-organic Frameworks (MOFs), which offers several potential advantages over currently used materials due to their higher drug loading capabilities and their high degree of modularity/reproducibility. In particular, we will target a new subclass of materials in which the Active Pharmaceutical Ingredient or API is directly encapsulated/incorporated in the MOF material during synthesis, thus avoiding the ineffective post-synthetic loading methods used to incorporate drugs into current release materials. Over the course of this research, we will work towards developing a universal protocol for the direct incorporation of any small molecule pharmaceutical into a controllable MOF drug release matrix. We will target the development of nano-crystalline materials with favorable drug release rates which can also be activated to release their drug payload when exposed to an appropriate stimulus such as light or a high acidity environment. This multi-disciplinary research program offers a unique training environment for the next generation of innovative Canadian scientists and involves aspects of inorganic chemistry, organic chemistry, and materials science. The advancement of nanotechnologies for drug release is a rapidly growing area, and this research program offers the possibility to develop better medications and new technologies within Canada, leading to an economic benefit and increased quality of life for all Canadians.